A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (NCT06413498)
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (117 Sites)
Showing the first 25 of 117 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Hospital — Gilbert, Arizona
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- UC San Diego Moores Cancer Center — San Diego, California
- UCLA Hematology/Oncology (Bowyer Infusion Clinic) — Santa Monica, California
- Stanford Cancer Institute — Stanford, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Sylvester Comprehensive Cancer Center — Coral Gables, Florida
- Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta — Newnan, Georgia
- St. Luke's Cancer Institute — Boise, Idaho
- University of Illinois Hospital and Health Sciences System — Chicago, Illinois
- IU Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Norton Cancer Institute, St. Matthews Campus — Louisville, Kentucky
- Ochsner Clinical Foundation — New Orleans, Louisiana
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Boston Medical Center — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Corewell Health - Lemmen-Holton Cancer Pavilion — Grand Rapids, Michigan
- Mayo Clinic — Rochester, Minnesota
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.